Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study-Reference-Cited by-同舟云学术

Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study

Published:2020-03 Issue: Volume:141 Page:89-96
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Wolff Henri B.^ORCID,Alberts Leonie,van der Linden Naomi,Bongers Mathilda L.,Verstegen Naomi E.^ORCID,Lagerwaard Frank J.,Hofman Frederik N.,Uyl-de Groot Carin A.,Senan Suresh^ORCID,El Sharouni Sherif Y.,Kastelijn Elisabeth A.,Schramel Franz M.N.H.,Coupé Veerle M.H.

Funder

Novartis Pharma BV

Boehringer Ingelheim

Astellas

Celgene

Sanofi

Janssen-Cilag

Bayer

Amgen

Gemzyme

Merck

Gilead

Novartis

Glycostem Therapeutics

Astra Zeneca

Roche

Varian Medical Systems

ViewRay Inc.

Eli Lily

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference46 articles.

1. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer;Goldstraw;J. Thorac. Oncol.,2016

2. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Postmus;Ann. Oncol.,2017

3. Niet-kleincellig longcarcinoom: Landelijke richtlijn, versie 2.3;Nederland,2015

4. Non-small cell lung cancer, version 2.2013;Ettinger;J. Compr. Canc. Netw.,2013

5. Assessment of health information technology interventions in evidence-based medicine: a systematic review by adopting a methodological evaluation framework;Christopoulou;Healthcare (Basel),2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Prospective Outcomes and Cost-Effective Analysis of Surgery Compared to Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer;2024-08-09

2. Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2024-05-20

3. Surgical-decision making in the setting of unsuspected N2 disease: a cost-effectiveness analysis;Journal of Thoracic Disease;2024-02

4. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy;PharmacoEconomics;2024-01-09

5. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States;Frontiers in Immunology;2023-09-26